https://sarveshhealthcity.wordpress.com/2025/12/04/what-is-the-recovery-time-for-acute-kidney-injury-aki-treatment/
💊 Why do some medications unexpectedly harm the kidneys — and can single-cell data uncover the reason?
🔗 Cell-type specific single-cell signatures reveal nephrotoxic drug effects. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.11.012
📚 CSBJ: https://www.csbj.org/
#Nephrotoxicity #CellBiology #Cheminformatics #AcuteKidneyInjury #DrugDiscovery #SingleCellGenomics #DrugDevelopment #CellAtlas
Background Acute kidney injury (AKI) is common in critically ill patients with coronavirus disease-19 (COVID-19). We aimed to explore the changes in AKI epidemiology between the first and the second COVID wave in the United Kingdom (UK). Methods This was an observational study of critically ill adult patients with COVID-19 in an expanded tertiary care intensive care unit (ICU) in London, UK. Baseline characteristics, organ support, COVID-19 treatments, and patient and kidney outcomes up to 90 days after discharge from hospital were compared. Results A total of 772 patients were included in the final analysis (68% male, mean age 56 ± 13.6). Compared with wave 1, patients in wave 2 were older, had higher body mass index and clinical frailty score, but lower baseline serum creatinine and C-reactive protein (CRP). The proportion of patients receiving invasive mechanical ventilation (MV) on ICU admission was lower in wave 2 (61% vs 80%; p < 0.001). AKI incidence within 14 days of ICU admission was 76% in wave 1 and 51% in wave 2 (p < 0.001); in wave 1, 32% received KRT compared with 13% in wave 2 (p < 0.001). Patients in wave 2 had significantly lower daily cumulative fluid balance (FB) than in wave 1. Fewer patients were dialysis dependent at 90 days in wave 2 (1% vs. 4%; p < 0.001). Conclusions In critically ill adult patients admitted to ICU with COVID-19, the risk of AKI and receipt of KRT significantly declined in the second wave. The trend was associated with less MV, lower PEEP and lower cumulative FB. Trial registration: NCT04445259.
Referenced link: https://medicalxpress.com/news/2022-10-peering-cells-reveals-key-acute.html
Discuss on https://discu.eu/q/https://medicalxpress.com/news/2022-10-peering-cells-reveals-key-acute.html
Originally posted by Phys.org / @[email protected]: https://twitter.com/medical_xpress/status/1577676255301931011#m
RT by @physorg_com: Peering into single cells reveals key processes in #acutekidneyinjury https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01108-9 https://medicalxpress.com/news/2022-10-peering-cells-reveals-key-acute.html
Acute kidney injury (AKI) is a frequent complication associated with various diseases and particularly affects patients on intensive care units. However, the mechanisms underlying AKI are incompletely understood. Just recently, an interdisciplinary research team has used single-cell sequencing techniques to uncover the molecular processes associated with AKI.